• Home
• Patronate
• International Advisory Board
• Meetings
• Publications
• Aims
• Contact

Meetings

Implications of Comorbidity for Etiology and Treatment of Neuropsychiatric Disorders

Mazagón (Huelva)

October 19 - 23 2005

The content of this congress, together with other contributions on the topic, are collected in vol. 8 of the series "Strategies for studying brain disorders"

PROGRAMME

• Tomas Palomo, Spain
  Opening Remarks
• German Berrios, UK.
  Comorbidity and Psychiatric Nosology

S1. GENETIC VARIATION UNDERLYING COMORBIDITY

• Douglas Blackwood, UK
  Common Genotypes in Schizophrenia and Depression
• Janet Hoenicka, Spain
  Genetic variants in Psychiatric Disorders
• Kenneth Blum, USA
  Genetic Variants underlying Reward Deficiency Syndrome
• Tomás Palomo, Spain
  Genetic Contributions to Psychopathic Traits in Alcoholic Patients
• Isidro Ferrer, Spain
  DNA chip technology in Brain Banks: Efficiency and Reliability for Neuropsychiatric Research

S2. NEURONAL SUBSTRATES OF COMORBIDITY IN ANIMAL MODELS

• Susan Totterdell, UK
  The Anatomy of Synaptic Interactions in Cortical and Limbic Regions
• Bita Moghaddam, USA
  Shared Pathways that support Addictive and Schizophrenia –like Behaviors
• Athina Markou, USA
  Design of Animal Models and Treatments for Addiction and Depression Comorbidity
• Peter Kalivas, UK
  Signal Transduction Mechanisms in Addiction and Schizophrenia
• Mark Geyer, USA
  The Family of Sensorimotor Gating Disorders: Comorbidities or Diagnostic Overlaps?
• Therese M. Jay, France
  Stress, Frontal Synaptic Plasticity and Psychotropic Drugs

S3. MOVEMENT DISORDERS IN PSYCHOTIC STATES

• Trevor Archer, Sweden
  Postnatal Iron Involvement in Motor Alterations pertaining to Psychosis-related Behaviour
• Peter Riederer, Germany
  Psychotics Stages in Parkinson´s Disease and Motor Symptoms in Schizophrenia: Basic Aspects
• Moussa Youdim, Israel
  Implications of Comorbidity for Etiology and Treament of Neurodegenerative Diseases with Multifunctional Drugs
• Werner Schmidt, Germany
  Behavioural Sensitization in Schizophrenia,Parkinson´s Disease and Dyskinesia

S4. IATROGENIC COMORBIDITY

• Richard J. Beninger, Canada
  Cognitive Effects of Antipsychotic Medications
• Michael Maes, Belgium
  Immunological Effects of Antipsychotics
• Richard M. Kostrzewa , USA
  Haloperidol-Induced Tardive Dyskinesia inRats, its Persistence after Discontinuation of Haloperidol, and Effective Treatments
• Abraham Weizman, Israel
  Comorbidity of Schizophrenia and OCD: Clinical Aspects, Neurobiology and Treatment

S5. COGNITION LEARNING AND COMORBIDITY

• Klaus Ebmeier, UK
  Cognitive Impairment in Major Depression (the fMRI perspective)?
• Brian Leonard, Ireland
  Changes in the Immune System in Depression and Dementia: Causal o Coincidental Effects?
• José María Delgado, Spain
  Experimental models for the Study of Cognitive Disorders
• Martín Cammarota, Brazil
  The consequences of Memory Expression
• Ivan Izquierdo, Brazil
  Further Learning moves Memory making Mechanisms from the Hippocampus to the Striatum

S6. COMORBIDITY IN ADDICTION WITH OTHER PSYCHIATRIC ILLNESSES

• Marta Torres, Spain
  Importance of Clinical Diagnoses for Comorbidity studies
• John Krystal, USA
  Comorbidity between Schizophrenia and Addiction
• Pierre Sokoloff, France
  BDNF: an Etiological Factor in Schizophrenia and Drug Addiction
• Alan I. Green, USA
  Pharmacotherapy for Schizophrenia and Co-occurring Substance Use Disorders
• Miguel Casas, Spain
  Dual Diagnosys in Physicians
• Cristine Barrowclough, UK
  Psychological Approaches to working with Psychosis and Substance Misusing Clients

S7. IMPLICATIONS OF COMORBIDITY FOR ETIOLOGY AND TREATMENT OF NEUROPSYCHIATRIC DISORDERS

• Antonio Lobo, Spain
  Depressive Comorbidity in patients with Somatic Pathology
• Henry Szechtman, Canada
  Obsessive-compulsive Disorder as a Disturbance of Security Motivation. The Immune function in Schizophrenia
• Vicente Molina, Spain
  Neuroimaging Profiles, Typical and Atypical Antipsychotics and Disease Evolution
• Tom G. Bolwig, Denmark
  Epilepsy and Affective Disorder
• Norbert Müller, Germany
  The Immune function in Schizophrenia
• Anthony Grace, USA
  Disruption of Cortical-Amygdala Interaction as a substrate for Co-morbidtity
• Joseph T. Coyle, USA
  Glutamate Transmission as a Common Mechanism in Co-morbid Psycopathologies

• Tomás Palomo, Spain
  Concluding Remarks

STRATEGIES FOR STUDYING BRAIN DISORDERS

© 2009 Fundación Cerebro y Mente All rights reserved